Drug intelligence / Profile preview

Gengud

Development stage: Unknown
Lead developer: Genspec Lifesciences
Modality: Small Molecules, Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Gengud is a multi-ingredient nutraceutical supplement developed by Genspec Lifesciences. It is formulated as an oral capsule containing a combination of 14 probiotic strains (28.125 billion CFU), omega-3 fatty acids (90mg eicosapentaenoic acid and 60mg docosahexaenoic acid), and vitamin E (400mg). The product is designed to support gut health and general wellness by modulating the gut microbiota, providing anti-inflammatory effects through omega-3 fatty acids, and offering antioxidant protection via vitamin E. It is marketed in India for the management of irritable bowel syndrome, diarrhea, allergic disorders, and the common cold, as well as for boosting immunity.

Brand names: Gengud
Other names: Probiotics + Omega-3 + Vitamin E

Targets

PPAR (PPAR family)

Beyond the preview

Go deeper on Gengud.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gengud.

Explore the full profile